BACKGROUND: Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy. METHODS: Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration. RESULTS: Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003). CONCLUSIONS: The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.
BACKGROUND: Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy. METHODS:Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration. RESULTS: Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003). CONCLUSIONS: The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.
Authors: Deborah Tomlinson; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; Lillian Sung Journal: Support Care Cancer Date: 2007-08-28 Impact factor: 3.603
Authors: Deborah Tomlinson; Faith Gibson; Nathaniel Treister; Christina Baggott; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; John Doyle; Brian Feldman; Lillian Sung Journal: Support Care Cancer Date: 2008-11-04 Impact factor: 3.603
Authors: Akram F Qutob; Gabrielle Allen; Sumant Gue; Tamas Revesz; Richard M Logan; Dorothy Keefe Journal: Support Care Cancer Date: 2012-10-26 Impact factor: 3.603
Authors: S Jacobs; C Baggott; R Agarwal; T Hesser; T Schechter; P Judd; D Tomlinson; J Beyene; L Sung Journal: Br J Cancer Date: 2013-10-15 Impact factor: 7.640